Hints and tips:
Related Special Reports
...There are also questions about the role of a company that acted as a middleman and why a contract was signed ahead of deals with other manufacturers, such as Pfizer and Janssen, even though the Covaxin shot...
...Najat Khan, chief data science officer and head of R&D strategy at Janssen, the pharmaceuticals arm of Johnson & Johnson, says it is building a bank of “bilingual talent”....
...There are also questions about the role played by a company that acted as intermediary and why the contract was signed ahead of deals with Pfizer and Johnson & Johnson’s pharma division Janssen, even though...
...This month Hong Kong-based Insilico Medicine inked a drug discovery deal with Janssen. Bayer recently backed US-based Recursion Pharmaceuticals....
...It is the largest deal struck by J&J since it acquired Actelion, the European biotech group, for about $30bn in 2017....
...A poll released in mid-December caused surprise in Germany — the country that has been at the forefront of the race for a vaccine with biotech company BioNTech — by showing that half of surveyed nurses did...
...Bharat Biotech INDIA Bharat Biotech’s vaccine has been developed with the Indian Council of Medical Research and the National Institute of Virology....
...He cites platforms such as Cocoon from Lonza, and another from Ori Biotech, which are automating and standardising cell and gene therapy manufacturing....
...Solomon was previously general counsel at the biotech start-up Velocity Sciences and Samadi joins from Milbank....
...In the UK, Genomics Plc, a spinout from the University of Oxford, signed a drug discovery deal with Vertex Pharmaceuticals, the biotech company....
...Hannah Kuchler is the FT’s US pharma and biotech correspondent Follow @FTMag on Twitter to find out about our latest stories first....
...Also moving to BeiGene last month was Vivian Xin Bian, previously a vice-president at Xian Janssen, a China joint-venture part owned by Johnson & Johnson....
...Mulvany is also no stranger to the space, in 2012 he sold his biotech company Proximagen to US drugmaker Upsher-Smith for £223m....
...“The Car-T technology is moving very quickly,” says Peter Lebowitz, global head of oncology at Janssen, the drugmaking unit of Johnson & Johnson....
...“The clinical data looked superior to anything else we’d seen,” says Peter Lebowitz, who heads up oncology research at Janssen, J&J’s drugmaking division. “The data were almost too good to believe.”...
...The sector deal also included investment in the UK biotech sector from Apple Tree Partners, a US investment fund. The fund’s commitment is expected to be up to $1bn....
...In a statement on Wednesday, Scott White, president at Janssen Biotech, a pharmaceuticals unit of J&J, said: “We are effectively competing on value and price and to date, Pfizer has failed to demonstrate...
...The US Food and Drug Administration is testing on animals a candidate from Okairos, a Swiss biotech company acquired by GlaxoSmithKline in 2013....
...Chief Executive, IONTAS Ewan McDowall Vice-President of Commercial Operations, UK & Ireland, Ipsen Dr John Chaddock Vice-President of Neurology, Ipsen Bioinnovation Mark Hicken Managing Director, Janssen...
...Shares of Isis Pharmaceuticals gained nearly 11 per cent to $69.19, after the company announced a collaboration with Janssen Biotech, a subsidiary of Johnson & Johnson, to develop drugs to treat autoimmune...
...In hot pursuit of Novartis are the US biotech companies Kite Pharma and Juno Therapeutics....
...So what was it that persuaded Merck to pay $3.85bn – more than triple Idenix’s market capitalisation before the deal – to buy the Boston-based biotech company in June?...
...Winter says that traditional big pharma companies were initially sceptical, and it was smaller US biotech companies – notably Genentech and Centocor (now known as Janssen Biotech) – that worked to develop...
...Paul Stoffels, worldwide chairman of Janssen, part of Johnson & Johnson, cites a different problem....
International Edition